Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Ankle-Brachial Index Changes Post Exercise and Its Effects on Patient-Centered Outcomes and Gait (ExerciseABI)

Exercise-Induced Ankle-Brachial Index Dynamics as a Predictive Marker in Peripheral Arterial Disease

The goal of this observational study or clinical trial is to investigate how exercise can affect different areas of a person's life, especially those people with vascular disease. This is important because exercise can be beneficial for people with vascular disease. The study could include any of the following: those aged 65 years of age and older, between the ages of 50-64 who smokes, has diabetes, high blood pressure, high cholesterol, or has a family member with vascular disease, between the ages of 18-49 with diabetes and one other factor listed above, or those with vascular disease. The main question[s] it aims to answer is if exercise testing can better predict vascular disease.

The following research questions will be addressed in this study:

  1. Does baseline ABI influence the magnitude and recovery trajectory of ABI following an acute bout of exercise across a spectrum of vascular function?
  2. What association does exercise-induced ABI changes have on patient-reported outcomes of quality of life and intermittent claudication?
  3. Do functional outcomes of gait speed, time to claudication, gait variables related to rest breaks in 6MWT, and walking distance predict the magnitude of exercise-induced ABI reduction?

Participants will :

  • complete various questionnaires and a routine screening for vascular disease *walk for 6 minutes at your own pace
  • additional vascular screening tests will be performed.

Studienübersicht

Status

Noch keine Rekrutierung

Detaillierte Beschreibung

The purpose of this study is to examine if dynamic, exercise induced changes in the ankle- brachial index (ABI) are associated with pain, quality of life, and functional outcomes to better characterize peripheral vascular disease.

Individuals will be screened for eligibility if they meet the inclusion criteria. All data collection will occur during a single laboratory visit. It is anticipated the research study will take 1-2 hours, with 1 visit total to complete the study.

The primary study endpoint is to assess the use of the ankle-brachial test after exercise. This will be accomplished when the proposed number of subjects have been enrolled and completed the proposed protocol. Secondarily, the study may be stopped due to lack of funding. The final endpoint will be the completion of all data analysis including long-term follow up data and preparation for dissemination of the research findings.

The primary safety endpoint will occur if the study participant is unable to complete any part of the protocol.

All participants will give written consent to participate in the study. Participants will be instructed to refrain from alcohol, caffeine, nicotine, and exercise for at least one hour prior to testing to minimize confounding physiological effects. Testing will occur in a temperature-controlled environment maintained between 74-78°F (23-26°C) to ensure thermal stability and vascular consistency. Participant information including age, body mass index (BMI), diabetes status, past medical history, smoking history, and a list of current medications will be collected.

Participants will be comfortably positioned supine with the head of bed flat and legs fully extended. A 10-minute rest period will precede the initial ABI test to allow for hemodynamic stabilization.

For all ABI measurements, systolic blood pressures will be measured at the brachial and dorsalis pedis or posterior tibial arteries in both lower extremities using a hand-held 8-10 MHz continuous wave Doppler ultrasound probe (Huntleigh or equivalent) and appropriately sized sphygmomanometer cuffs. See Appendix A for ABI procedure details.

The order of arterial site measurements for initial resting ABI will be determined using a computer-generated randomization schedule. The limb exhibiting the lowest resting ABI will be selected for inclusion in the statistical analysis. The ABI will be calculated as the ratio of the higher ankle systolic pressure (either dorsalis pedis or posterior tibial) to the higher brachial systolic pressure (left or right arm). All data will be recorded to the nearest 2 mmHg.

Participants will then complete a 6-minute walk test, up to max pain on the 1 to 5 Claudication Symptom Rating Scale, to elicit claudication symptoms. ABI immediately post-exercise and at 1-, 3-, and 5-minute recovery intervals will be assessed in the same position as the resting ABI.

A participant will be considered to have completed the study after participating in the single visit. No in person follow up visits are anticipated.

Demographic history and SF-36 questionnaire may be collected by phone if needed.

Participation in this study is completely voluntary, and subjects can withdraw at any time. No specimens are associated with this study. All data will be stored according to study and subject number on an LSU network server. Electronic data and analysis will be retained for a minimum of seven years after study closure, and indefinitely after that.

Standard research practices will be used to document informed consent and schedule study visits. Consented subjects will be assigned a study number. A subject log relating subject name and subject number will be maintained by study personnel on a secure computer workstation by Dr Murnane in the School of Health Professions. Original signed and dated documents for all subjects will be securely maintained in the School of Health Professions.

A research team member will contact and discuss the study with potential participants to assess his/her interest in participating. The study design outlines methods of ensuring ongoing consent. Formal consent and signing of the consent form will occur in the School of Allied Health Professions or vascular clinic at Ochsner LSU Health Shreveport with a member of the study team before any testing begins.

Subjects will have the opportunity to ask questions and decline participation in this study. A copy of the informed consent will be provided to the subject.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

85

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Louisiana
      • Shreveport, Louisiana, Vereinigte Staaten, 71130
        • LSU Health Shreveport
        • Kontakt:
        • Hauptermittler:
          • Sarah Murnane, PT, DPT, PhD(c)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

recruited from local outpatient rehabilitation, vascular, and internal medicine clinics

Beschreibung

Inclusion Criteria

  • individuals over 65 years of age
  • individuals aged 50-64 with a risk factor for atherosclerosis including diabetes mellitus, history of smoking, hyperlipidemia, hypertension, or family history of peripheral arterial disease (PAD)
  • individuals aged 18-50 with diabetes mellitus and one additional risk factor for atherosclerosis as noted above, or
  • individuals with known atherosclerotic disease in another vascular bed including the coronary, carotid, subclavian, renal, or mesenteric artery stenosis, and individuals with known PAD

Exclusion Criteria

  • contraindications to brachial and/or ankle pressure measurement including history of deep vein thrombosis
  • lymphedema of the arms or legs
  • history of mastectomy or current leg ulceration preventing placement of a blood pressure cuff around the lower leg
  • an inability to lie in a supine position for 15 min
  • self-reported inability to walk for 6 minutes
  • severe cardiac or pulmonary disease limiting exercise
  • inability to obtain a Dopplerable pulse
  • noncompressible arteries (ABI >1.4)
  • those unable to consent

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
study participants
baseline ABI

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
magnitude of ABI reduction
Zeitfenster: immediately after exercise, at 1-, 3-, and 5-minute recovery intervals.
Measured as both absolute and percent change, calculated as the difference between baseline ABI and ABI immediately after exercise, at 1-, 3-, and 5-minute recovery intervals.
immediately after exercise, at 1-, 3-, and 5-minute recovery intervals.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Short-Form 36 (SF-36)
Zeitfenster: prior to baseline ABI testing
A generic outcome survey to quantify health status and health-related quality of life over 8 health domains. Minimum possible score is 0 and maximum possible score is 100. A higher score indicates better health condition, complete functioning, or absence of limitations.
prior to baseline ABI testing
International Physical Activity Questionnaire (IPAQ)
Zeitfenster: 3 times including at rest prior to 6MWT, at minute 3 and again at minute 6 during 6MWT

The IPAQ classifies individuals into low/moderate/high activity levels based on their subjective report of frequency, duration, and intensity of walking, moderate, and vigorous activity. Scoring for the IPAQ places individuals into a level based on their categorical score:

Low Those who not meet criteria for categories 2 or 3 are considered low/inactive. Moderate

Any one of the following three criteria:

  • 3 or more days of vigorous activity of at least 20 minutes per day OR
  • 5 or more days of moderate-intensity activity or walking of at least 30 min per day OR
  • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-min/week.

High

Any one of the following two criteria:

  • Vigorous-intensity activity on at least 3 days and accumulate at least 1500 MET-min/week OR
  • 7 or more days of any combo of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 3000 MET-min/week
3 times including at rest prior to 6MWT, at minute 3 and again at minute 6 during 6MWT
Gait speed
Zeitfenster: gait speed between minute 0-1, minute 3-4, and minute 5-6 of 6MWT
Gait speed is measured as the time taken to walk a fixed distance of 4-meters measured in meters per second (m/s) taken at a set time during the 6MWT.
gait speed between minute 0-1, minute 3-4, and minute 5-6 of 6MWT
Time to first standing rest break
Zeitfenster: 1time during 6MWT
The time until the participant takes their first standing rest break during the 6MWT, measured in seconds (s)
1time during 6MWT
Total duration of all standing rest breaks
Zeitfenster: 1 time during 6MWT
The total time duration, measured in seconds, of all standing rest breaks taken by the participant during the 6MWT.
1 time during 6MWT
Number of standing rest breaks
Zeitfenster: 1 time during the 6MWT
The number of standing rest breaks taken by a participant during the 6MWT.
1 time during the 6MWT
First standing rest break
Zeitfenster: During the 6MWT
The distance to first standing rest break, measured in meters (m), during the 6MWT.
During the 6MWT
Total walking distance
Zeitfenster: 1 time during the 6MWT
The total walking distance prior to participant sitting down during the 6MWT, measured in meters (m).
1 time during the 6MWT

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juni 2026

Primärer Abschluss (Geschätzt)

1. Juni 2027

Studienabschluss (Geschätzt)

1. Januar 2028

Studienanmeldedaten

Zuerst eingereicht

26. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. Juni 2026

Zuerst gepostet (Tatsächlich)

9. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. Juni 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Beschreibung des IPD-Plans

Would need to explore institutional requirements

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren